Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST)

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 32, 2010, Pages 14333-14338

  Gupta, Anu ^a   Roy, Srirupa ^b   Lazar, Alexander J F ^c   Wang, Wei Lien ^c   McAuliffe, John C ^c,d   Reynoso, David ^c   McMahon, James ^a   Taguchi, Takahiro ^e   Floris, Giuseppe ^f   Debiec Rychter, Maria ^f   Schoffski, Patrick ^f   Trent, Jonathan A ^c   Debnath, Jayanta ^b   Rubin, Brian P ^a,g  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e KOCHI UNIVERSITY   (Japan)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Imatinib; Quiescence; Targeted therapy

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; IMATINIB; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MEPACRINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR A; UNCLASSIFIED DRUG; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL DEATH; CYTOTOXICITY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL; CELL SURVIVAL; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; PATHOLOGY;

ANTIMALARIALS; AUTOPHAGY; CELL DEATH; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PYRIMIDINES;

EID: 77956282607     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1000248107     Document Type: Article

References (31)

1. Rubin BP, Heinrich MC, Corless CL (2007) Gastrointestinal stromal tumour. Lancet 369:1731-1741.
2. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G (2002) Clinical management of gastrointestinal stromal tumors: Before and after STI-571. Hum Pathol 33:466-477. (Pubitemid 34747865)
3. Blanke CD, et al. (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620-625. (Pubitemid 351264357)
4. Blay JY, et al. (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 25:1107-1113.
5. Heinrich MC, et al. (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764-4774. (Pubitemid 46630941)
6. Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132:27-42.
7. Klionsky DJ (2007) Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 8:931-937.
8. Debnath J, Baehrecke EH, Kroemer G (2005) Does autophagy contribute to cell death? Autophagy 1:66-74.
9. Thorburn A (2008) Apoptosis and autophagy: Regulatory connections between two supposedly different processes. Apoptosis 13:1-9.
10. Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726-734. (Pubitemid 41486365)
11. Ron D, Walter P (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8:519-529. (Pubitemid 46985379)
12. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9-22.
13. Agaram NP, et al. (2007) Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 13:170-181.
14. Klionsky DJ, et al. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4:151-175.
15. Kabeya Y, et al. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19:5720-5728.
16. Kimura S, Noda T, Yoshimori T (2007) Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 3:452-460. (Pubitemid 47293726)
17. Tanida I, Minematsu-Ikeguchi N, Ueno T, Kominami E (2005) Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy 1:84-91.
18. Bjørkøy G, et al. (2005) p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 171:603-614. (Pubitemid 41668720)
19. McAuliffe JC, et al. (2009) A randomized, phase II study of preoperative plus postoperative imatinib in GIST: Evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 16:910-919.
20. Heinrich MC, et al. (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26:5360-5367.
21. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8:741-752. (Pubitemid 47312826)
22. Bellodi C, et al. (2009) Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 119:1109-1123.
23. Degtyarev M, et al. (2008) Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 183:101-116.
24. Chou T (1991) The median-effect principle and the combination index for quantitation of synergism and antagonism. Synergism and antagonism in chemotherapy, eds Chou TR, Rideout DC (Academic, San Diego), pp 61-102.
25. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
26. Ertmer A, et al. (2007) The anticancer drug imatinib induces cellular autophagy. Leukemia 21:936-942. (Pubitemid 46672069)
27. Shingu T, et al. (2009) Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells. Int J Cancer 124:1060-1071.
28. Lorincz A, et al. (2008) Progenitors of interstitial cells of cajal in the postnatal murine stomach. Gastroenterology 134:1083-1093. (Pubitemid 351451982)
29. Roberts CJ, Raymond CK, Yamashiro CT, Stevens TH (1991) Methods for studying the yeast vacuole. Methods Enzymol 194:644-661.
30. Guo C, et al. (2009) 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene 28:1151-1161.
31. Gurova KV, et al. (2005) Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 102:17448-17453.